Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-15512 Safety and Drop Attributes in Dry Eye Disease
NCT06660290Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jan 2025
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of acoltremon in dry eye disease (DED) (4 arms), sponsored by Alcon Inc. Primary endpoint: Percentage of Subjects With Ocular Treatment-Emergent Adverse Events Attributed to Study Intervention at Day 1. Started Jan 2025; status: completed.
02
Drugs
acoltremon
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06660290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660290.